Design and development of thiolated graphene oxide nanosheets for brain tumor targeting

Ajinkya N. Nikam; Mahesh P. More; Abhijeet P. Pandey; Pravin O. Patil; Ashwini G. Patil; Prashant K. Deshmukh

doi:10.1080/00914037.2019.1596911

Design and development of thiolated graphene oxide nanosheets for brain tumor targeting

Ajinkya N. Nikam, Mahesh P. More, Abhijeet P. Pandey, Pravin O. Patil, Ashwini G. Patil, Prashant K. Deshmukh

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

The present investigation emphasizes on synthesis and characterization of thiol functionalized reduced graphene oxide (TrGO) as a novel platform for loading of anticancer drug methotrexate (TrGO-MTX), through amide bonding. Thiolation of graphene oxide (GO) was achieved by transesterification process. The introduction of sulfur containing chemical groups and the partial reduction of GO to TrGO were proven by analytical techniques. Thiol content was found to be 6.98 mM by Ellman’s method in a quantitative manner. Furthermore, antineoplastic action of TrGO-MTX against human glioblastoma astrocytom U-373 MG cell line was studied, wherein TrGO-MTX demonstrated significant inhibition rate as compared with pure MTX.

Original language	English
Journal	International Journal of Polymeric Materials and Polymeric Biomaterials
DOIs	https://doi.org/10.1080/00914037.2019.1596911
Publication status	Published - 02-07-2019
Externally published	Yes

All Science Journal Classification (ASJC) codes

Analytical Chemistry
Chemical Engineering(all)
Polymers and Plastics

Access to Document

10.1080/00914037.2019.1596911

Cite this

@article{cc96997c0cbf40808ac9bf416ca1a9dd,

title = "Design and development of thiolated graphene oxide nanosheets for brain tumor targeting",

abstract = "The present investigation emphasizes on synthesis and characterization of thiol functionalized reduced graphene oxide (TrGO) as a novel platform for loading of anticancer drug methotrexate (TrGO-MTX), through amide bonding. Thiolation of graphene oxide (GO) was achieved by transesterification process. The introduction of sulfur containing chemical groups and the partial reduction of GO to TrGO were proven by analytical techniques. Thiol content was found to be 6.98 mM by Ellman{\textquoteright}s method in a quantitative manner. Furthermore, antineoplastic action of TrGO-MTX against human glioblastoma astrocytom U-373 MG cell line was studied, wherein TrGO-MTX demonstrated significant inhibition rate as compared with pure MTX.",

author = "Nikam, {Ajinkya N.} and More, {Mahesh P.} and Pandey, {Abhijeet P.} and Patil, {Pravin O.} and Patil, {Ashwini G.} and Deshmukh, {Prashant K.}",

year = "2019",

month = jul,

day = "2",

doi = "10.1080/00914037.2019.1596911",

language = "English",

journal = "International Journal of Polymeric Materials and Polymeric Biomaterials",

issn = "0091-4037",

publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Design and development of thiolated graphene oxide nanosheets for brain tumor targeting

AU - Nikam, Ajinkya N.

AU - More, Mahesh P.

AU - Pandey, Abhijeet P.

AU - Patil, Pravin O.

AU - Patil, Ashwini G.

AU - Deshmukh, Prashant K.

PY - 2019/7/2

Y1 - 2019/7/2

N2 - The present investigation emphasizes on synthesis and characterization of thiol functionalized reduced graphene oxide (TrGO) as a novel platform for loading of anticancer drug methotrexate (TrGO-MTX), through amide bonding. Thiolation of graphene oxide (GO) was achieved by transesterification process. The introduction of sulfur containing chemical groups and the partial reduction of GO to TrGO were proven by analytical techniques. Thiol content was found to be 6.98 mM by Ellman’s method in a quantitative manner. Furthermore, antineoplastic action of TrGO-MTX against human glioblastoma astrocytom U-373 MG cell line was studied, wherein TrGO-MTX demonstrated significant inhibition rate as compared with pure MTX.

AB - The present investigation emphasizes on synthesis and characterization of thiol functionalized reduced graphene oxide (TrGO) as a novel platform for loading of anticancer drug methotrexate (TrGO-MTX), through amide bonding. Thiolation of graphene oxide (GO) was achieved by transesterification process. The introduction of sulfur containing chemical groups and the partial reduction of GO to TrGO were proven by analytical techniques. Thiol content was found to be 6.98 mM by Ellman’s method in a quantitative manner. Furthermore, antineoplastic action of TrGO-MTX against human glioblastoma astrocytom U-373 MG cell line was studied, wherein TrGO-MTX demonstrated significant inhibition rate as compared with pure MTX.

UR - http://www.scopus.com/inward/record.url?scp=85064627611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064627611&partnerID=8YFLogxK

U2 - 10.1080/00914037.2019.1596911

DO - 10.1080/00914037.2019.1596911

M3 - Article

AN - SCOPUS:85064627611

SN - 0091-4037

JO - International Journal of Polymeric Materials and Polymeric Biomaterials

JF - International Journal of Polymeric Materials and Polymeric Biomaterials

ER -

Design and development of thiolated graphene oxide nanosheets for brain tumor targeting

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this